TXG
10x GenomicsCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull thesis: successful commercial translation of multi-omics and single-cell expansion leads to sustained top-line growth, operating leverage, and re-rating toward premium instrument/computational peers.
Posture
Mixed
Lead driver
Momentum
What changed
6 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Execution risk scaling manufacturing and sales
Momentum
87
Value
50
Sentiment
10
Setup hits (3d)
6 · Net Bullish
AI TargetsBase $18.54 · Bull $27.18 · Bear $12.68
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-02-14 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $20.07
Why
Momentum87 · Δ7d +13.6
Value50 · Δ7d -0.3
Sentiment10 · Δ7d -14.1
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
87
34% active weight
Current posture
7d trendImproving
Δ7d
+13.6
Δ21d
+25.0
Value
50
32% active weight
Current posture
7d trendFlat
Δ7d
-0.3
Δ21d
-0.4
Sentiment
10
33% active weight
Current posture
7d trendSoftening
Δ7d
-14.1
Δ21d
-22.4
Why this grade
Composite grade C. Momentum 87.4 / Value 49.8 / Sentiment 10.3
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$3.76B
Beta
2.23
Shares Out
126.55M
P/E (TTM) · Derived
-85.0
P/S (TTM)
3.61
P/FCF (TTM)
28.39
Rev YoY
-1.7%
EPS YoY
+26.1%
Gross Margin
+68.9%
Op Margin
-14.2%
Net Debt
-$393.4M
Current Ratio
4.48
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology